GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
6.68
+0.72 (12.08%)
At close: Oct 9, 2026, 4:00 PM EDT
6.80
+0.12 (1.80%)
After-hours: Oct 9, 2026, 7:56 PM EDT
GT Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1
Market Cap
12.05M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 27.00K | -34.00K | -55.74% |
| Dec 31, 2014 | 61.00K | -307.00K | -83.42% |
| Dec 31, 2013 | 368.00K | 26.00K | 7.60% |
| Dec 31, 2012 | 342.00K | 316.00K | 1,215.38% |
| Dec 31, 2011 | 26.00K | 15.00K | 136.36% |
| Dec 31, 2010 | 11.00K | -37.00K | -77.08% |
| Dec 31, 2009 | 48.00K | -1.10M | -95.80% |
| Dec 31, 2008 | 1.14M | -581.00K | -33.70% |
| Dec 31, 2007 | 1.72M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vistagen Therapeutics | 2.50M |
| BioLineRx | 1.39M |
| Daré Bioscience | 1.37M |
| Pluri | 1.02M |
| CytoMed Therapeutics | 609.73K |
GTBP News
- 16 hours ago - GT Biopharma registers to sell 13.5M shares of common stock for holders - TheFly
- 1 day ago - GT Biopharma Registration statement: Registration filing - Filings
- 8 days ago - GT Biopharma Proxy statement: Proxy filing - Filings
- 25 days ago - GT Biopharma trading resumes - TheFly
- 25 days ago - GT Biopharma trading halted, volatility trading pause - TheFly
- 25 days ago - GT Biopharma announces IND clearance from FDA for GTB-5550 in multiple myeloma - TheFly
- 25 days ago - GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma - GlobeNewsWire
- 4 weeks ago - GT Biopharma Transcript: Status update - Transcripts